Skip to content

Antares Pharma, Inc.: 10-Q filed 2011-11-08

What Antares Pharma, Inc. reported in its quarterly report filed 2011-11-08 (fiscal Q3 2011): 37 published measures, 94 facts as tagged in accession 0001016169-11-000027.

This filing

Form
10-Q (quarterly report)
Filed
2011-11-08
Fiscal period
fiscal Q3 2011
Accession
0001016169-11-000027 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Antares Pharma, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2011-09-3038,495,702USD
At 2010-12-3115,141,302USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2011-09-307,600,928USD
At 2010-12-318,514,684USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2011-09-3030,894,774USD
At 2010-12-316,626,618USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2011-09-3017,118,832USD
At 2010-12-319,847,813USD
At 2010-09-3010,227,084USD
At 2009-12-3113,559,088USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2011-07-01 to 2011-09-30-1,299,259USD92
2011-01-01 to 2011-09-30-4,233,989USD273
2010-07-01 to 2010-09-30-1,631,400USD92
2010-01-01 to 2010-09-30-4,792,597USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2011-01-01 to 2011-09-30-4,337,257USD273
2010-01-01 to 2010-09-30-5,325,799USD273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2011-01-01 to 2011-09-30227,763USD273
2010-01-01 to 2010-09-3061,621USD273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2011-07-01 to 2011-09-303,919,037USD92
2011-01-01 to 2011-09-3011,031,457USD273
2010-07-01 to 2010-09-303,122,060USD92
2010-01-01 to 2010-09-309,537,133USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2011-01-01 to 2011-09-3027,020,327USD273
2010-01-01 to 2010-09-302,035,480USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2011-01-01 to 2011-09-30-15,405,394USD273
2010-01-01 to 2010-09-30-128,837USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2011-09-30-141,207,784USD
At 2010-12-31-136,973,795USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2011-09-30494,075USD
At 2010-12-31327,535USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2011-01-01 to 2011-09-301,488,887USD273
2010-01-01 to 2010-09-30889,188USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2011-07-01 to 2011-09-30-1,266,501USD92
2011-01-01 to 2011-09-30-4,274,426USD273
2010-07-01 to 2010-09-30-1,664,957USD92
2010-01-01 to 2010-09-30-4,800,825USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2011-09-3029,905,620USD
At 2010-12-3112,475,510USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2011-09-306,761,133USD
At 2010-12-316,672,090USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2011-09-301,829,387USD
At 2010-12-311,773,259USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2011-09-301,095,355USD
At 2010-12-311,095,355USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2011-09-30921,563USD
At 2010-12-31803,426USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2011-09-301,986,786USD
At 2010-12-311,245,560USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2011-07-01 to 2011-09-303,378,488USD92
2011-01-01 to 2011-09-3010,652,703USD273
2010-07-01 to 2010-09-303,707,503USD92
2010-01-01 to 2010-09-3010,947,504USD273

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2011-09-30351,494USD
At 2010-12-31272,463USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2011-07-01 to 2011-09-302,111,987USD92
2011-01-01 to 2011-09-306,378,277USD273
2010-07-01 to 2010-09-302,042,546USD92
2010-01-01 to 2010-09-306,146,679USD273

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2011-07-01 to 2011-09-301,807,050USD92
2011-01-01 to 2011-09-304,653,180USD273
2010-07-01 to 2010-09-301,079,514USD92
2010-01-01 to 2010-09-303,390,454USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2011-07-01 to 2011-09-301,429,210USD92
2011-01-01 to 2011-09-305,124,877USD273
2010-07-01 to 2010-09-302,332,712USD92
2010-01-01 to 2010-09-306,661,325USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2011-09-30103,509,310shares
At 2010-12-3184,157,865shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2011-09-30-566,907USD
At 2010-12-31-559,837USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2011-09-3031,424USD
At 2010-12-3131,226USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2011-09-301,652,957USD
At 2010-12-311,818,769USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2011-09-30255,027USD
At 2010-12-31193,985USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2011-07-01 to 2011-09-301,559,018USD92
2011-01-01 to 2011-09-304,325,699USD273
2010-07-01 to 2010-09-301,170,041USD92
2010-01-01 to 2010-09-303,509,630USD273

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2011-01-01 to 2011-09-30121,469USD273
2010-01-01 to 2010-09-30137,492USD273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2011-07-01 to 2011-09-30-32,758USD92
2011-01-01 to 2011-09-3040,437USD273
2010-07-01 to 2010-09-3033,557USD92
2010-01-01 to 2010-09-308,228USD273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2011-01-01 to 2011-09-3021,280,718USD273
2010-01-01 to 2010-09-300USD273

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2011-01-01 to 2011-09-30-744,700USD273
2010-01-01 to 2010-09-30626,165USD273

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2011-01-01 to 2011-09-30-79,031USD273
2010-01-01 to 2010-09-3042,596USD273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2011-01-01 to 2011-09-3055,503USD273
2010-01-01 to 2010-09-30-292,715USD273

Inspect the source

Entity
Antares Pharma, Inc. / CIK 0001016169
Captured
SEC response SHA-256
540b8a117c7898b4d835a42d9aec42c261c74ea0da49d4755fcc6f2d9b68be71

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001016169.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))